National Planning Corp Takes Position in Bluebird Bio Inc. (BLUE)
National Planning Corp bought a new stake in Bluebird Bio Inc. (NASDAQ:BLUE) during the second quarter, Holdings Channel reports. The firm bought 4,440 shares of the company’s stock, valued at approximately $246,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP acquired a new position in Bluebird Bio during the first quarter valued at $51,095,000. State Street Corp raised its position in Bluebird Bio by 25.9% in the first quarter. State Street Corp now owns 1,201,936 shares of the company’s stock valued at $51,088,000 after buying an additional 247,254 shares in the last quarter. Norges Bank acquired a new position in Bluebird Bio during the fourth quarter valued at $15,492,000. RTW Investments LLC acquired a new position in Bluebird Bio during the first quarter valued at $9,621,000. Finally, Franklin Resources Inc. raised its position in Bluebird Bio by 26.1% in the first quarter. Franklin Resources Inc. now owns 965,561 shares of the company’s stock valued at $41,036,000 after buying an additional 199,900 shares in the last quarter.
Shares of Bluebird Bio Inc. (NASDAQ:BLUE) traded up 2.42% during trading on Monday, reaching $73.20. The company’s stock had a trading volume of 558,265 shares. Bluebird Bio Inc. has a 12 month low of $35.37 and a 12 month high of $143.08. The firm’s market cap is $2.72 billion. The stock’s 50 day moving average price is $54.41 and its 200-day moving average price is $47.27.
Bluebird Bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.15. The company had revenue of $1.55 million for the quarter, compared to the consensus estimate of $2.01 million. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. Bluebird Bio’s revenue for the quarter was down 68.6% compared to the same quarter last year. During the same period last year, the company earned ($1.57) EPS. Equities analysts predict that Bluebird Bio Inc. will post ($6.16) EPS for the current year.
BLUE has been the topic of several recent analyst reports. Goldman Sachs Group Inc. upgraded Bluebird Bio from a “buy” rating to a “conviction-buy” rating and set a $135.00 target price on the stock in a report on Thursday. Maxim Group reiterated a “buy” rating and set a $85.00 target price (down from $105.00) on shares of Bluebird Bio in a report on Thursday, August 4th. BTIG Research reiterated a “buy” rating and set a $72.00 target price on shares of Bluebird Bio in a report on Wednesday, June 29th. Jefferies Group reissued a “positive” rating and issued a $80.00 price target on shares of Bluebird Bio in a research note on Thursday, July 14th. Finally, Wedbush reissued an “outperform” rating and issued a $117.00 price target on shares of Bluebird Bio in a research note on Thursday, September 8th. Six research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $87.39.
In other news, insider David Davidson sold 1,000 shares of the stock in a transaction dated Friday, July 15th. The shares were sold at an average price of $45.08, for a total transaction of $45,080.00. Following the transaction, the insider now owns 10,600 shares of the company’s stock, valued at approximately $477,848. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Sullivan sold 2,807 shares of the stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $45.04, for a total transaction of $126,427.28. Following the transaction, the insider now directly owns 4,656 shares in the company, valued at approximately $209,706.24. The disclosure for this sale can be found here. Insiders own 3.50% of the company’s stock.
Bluebird Bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bluebird Bio Inc. (NASDAQ:BLUE).
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.